Tadekinig alfa
Primary HLH (NLRC4 mutation, XIAP deficiency)
Key Facts
About AB2 Bio
AB2 Bio is a clinical-stage biotechnology company developing targeted therapies for severe inflammatory diseases, with a core focus on IL-18-driven conditions like Hemophagocytic Lymphohistiocytosis (HLH) and Adult-Onset Still's Disease (AOSD). Its lead candidate, Tadekinig alfa, a recombinant human IL-18 binding protein, has demonstrated a strong safety profile in early trials and is now in a pivotal Phase 3 study for primary HLH. The company recently secured a significant U.S. option and licensing agreement with Nippon Shinyaku, validating its approach and providing a potential path to commercialization. AB2 Bio operates as a private, pre-revenue entity leveraging its academic roots at EPFL to address niche, high-severity autoimmune disorders.
View full company profileAbout AB2 Bio
AB2 Bio is a clinical-stage biotechnology company developing targeted therapies for severe inflammatory diseases, with a core focus on IL-18-driven conditions like Hemophagocytic Lymphohistiocytosis (HLH) and Adult-Onset Still's Disease (AOSD). Its lead candidate, Tadekinig alfa, a recombinant human IL-18 binding protein, has demonstrated a strong safety profile in early trials and is now in a pivotal Phase 3 study for primary HLH. The company recently secured a significant U.S. option and licensing agreement with Nippon Shinyaku, validating its approach and providing a potential path to commercialization. AB2 Bio operates as a private, pre-revenue entity leveraging its academic roots at EPFL to address niche, high-severity autoimmune disorders.
View full company profileAbout AB2 Bio
AB2 Bio is a clinical-stage biotechnology company developing targeted therapies for severe inflammatory diseases, with a core focus on IL-18-driven conditions like Hemophagocytic Lymphohistiocytosis (HLH) and Adult-Onset Still's Disease (AOSD). Its lead candidate, Tadekinig alfa, a recombinant human IL-18 binding protein, has demonstrated a strong safety profile in early trials and is now in a pivotal Phase 3 study for primary HLH. The company recently secured a significant U.S. option and licensing agreement with Nippon Shinyaku, validating its approach and providing a potential path to commercialization. AB2 Bio operates as a private, pre-revenue entity leveraging its academic roots at EPFL to address niche, high-severity autoimmune disorders.
View full company profile